Can an Automated TFF System be used in a multi - product environment?

If you’ve spent any time in biomanufacturing, pharmaceutical development, or biotech labs scaling from R&D to commercial production, you know that multi-product environments aren’t just a convenience—they’re a necessity. Many facilities, from contract development and manufacturing organizations (CDMOs) to mid-sized biotechs, handle multiple products side by side: monoclonal antibodies (mAbs), gene therapies, vaccines, and even cell culture products, all with vastly different process requirements. That’s where tangential flow filtration (TFF) comes in. TFF is a workhorse for downstream processing, used for concentration, buffer exchange, and clarification, but the question I hear most from facility managers is: Can an Automated TFF System hold up in a multi-product environment?

As a supplier of TFF systems, I’ve watched firsthand how manual TFF setups struggled to keep pace with the demands of multi-product workflows—batch-to-batch variability, long changeover times, and high risk of cross-contamination. When we launched our Automated TFF System, we built it explicitly to solve those pain points, but I wanted to dig deeper into whether this technology truly delivers for teams juggling multiple products. Let’s break down the science, the real-world applications, and the proof that automated TFF is more than capable of supporting a flexible multi-product environment.

First, let’s ground this in why multi-product TFF is so tricky. Every product has unique characteristics: mAbs require tight molecular weight cutoffs (MWCOs) for concentration and gentle buffer exchange, viral vectors need low shear forces to preserve integrity, and cell culture harvests demand efficient clarification without clogging membranes. Manual TFF setups rely on operators to adjust flow rates, transmembrane pressure (TMP), and diafiltration (DF) volumes between batches—a process that’s slow, inconsistent, and prone to human error. For a facility running 10+ different products monthly, this leads to extended changeover times, which eat into production capacity and drive up costs. Cross-contamination is another major risk: residual product from a previous batch left in tubing or filters can ruin a high-value next product, triggering costly reworks or regulatory delays.

This is where automation steps in. An Automated TFF System standardizes process parameters, eliminates manual adjustments, and integrates clean-in-place (CIP) and steam-in-place (SIP) protocols that are critical for multi-product operation. But let’s get specific about the technical features that make this work, because “automation” is a broad term. Our Automated TFF System, for example, is designed with modular configurations that let teams swap out filters, adjust flow paths, and tweak process logic for different products quickly. It’s not a one-size-fits-all unit; it’s a flexible platform that adapts to your products, not the other way around.

Take membrane compatibility, for instance. Different TFF applications use different membrane types and sizes: microfiltration (MF) for cell clarification, ultrafiltration (UF) for concentration, and even specialized membranes for viral clearance. Our line includes Microfiltration TFF System options for cell-based products, Ultrafiltration TFF System for mAbs and protein concentration, and Pilot Scale TFF System units that scale seamlessly from R&D to small commercial runs—all compatible with our automated control software. The key here is that the automation platform doesn’t lock you into a single membrane type; it lets you program unique process recipes for each product, so when you switch from a vaccine to a gene therapy, you can pull up the pre-validated recipe for that application without reconfiguring pressure, flow, or diafiltration steps manually.

Process consistency is another big win for multi-product environments. A study published in Biotechnology Progress found that manual TFF operations had up to 12% batch-to-batch variability in product concentration, compared to less than 2% with automated systems. That’s a game-changer when you’re running multiple products, because it means every batch—regardless of which product it is—meets regulatory specifications (like ICH Q7 guidelines for biomanufacturing) without extra QC testing. For a CDMO that serves multiple clients, this consistency builds trust: clients know their product will be processed exactly as specified, every time, even when it’s part of a busy multi-product schedule.

But what about cross-contamination? That’s a top concern for teams switching between products with very different compositions. Our Automated TFF System includes integrated CIP cycles that are fully programmable, so you can tailor the CIP solution concentration, flow rate, and contact time based on the previous product and the next one. For example, if you process a high-titer mAb batch, the system can run a 2-hour CIP with 0.1 M NaOH, then rinse with buffer, then prepare for a viral vector batch with a shorter, gentler CIP that preserves the integrity of the vector’s capsid. We also offer Flexible Tangential Flow Filtration Devices with quick-disconnect tubing and filter housings that reduce the amount of residual product left in the system between batches—minimizing the risk of carryover even when processing structurally similar products.

I’ve seen this work firsthand with a client mid-sized biotech that makes both mAbs and adeno-associated virus (AAV) vectors for clinical trials. Before switching to an automated TFF system, they were spending 8 hours on changeover between batches, with a 5% risk of cross-contamination between their mAb and AAV runs. After implementing our Automated TFF System, their changeover time dropped to 90 minutes, and cross-contamination incidents were eliminated. They told us that they can now process 30% more batches per month, because they’re losing less time to manual adjustments and reworks. That’s the kind of efficiency that makes multi-product operations viable.

Of course, multi-product environments also include scale ranges—from small R&D batches (milliliters) to commercial production batches (thousands of liters). Our Pilot Scale TFF System is designed to mirror the control logic of our larger commercial automated systems, so teams don’t have to re-validate processes when scaling up. That’s critical for multi-product facilities that move products from R&D to commercialization while supporting existing products. The automated platform ensures that process parameters (like TMP, cross-flow rate, and diafiltration volume) remain consistent across scales, which reduces validation time and regulatory burden.

But is there a limit to what automated TFF can handle in multi-product settings? The short answer is no—when the system is designed with flexibility at its core. We’ve worked with clients that run 15+ different products, including vaccines, recombinant proteins, and cell culture media, all on the same automated TFF platform. The key is that the system isn’t just automated—it’s modular, with software that’s easy to update, and process components that can be swapped out quickly. Some newer automated systems even integrate with facility-wide LIMS (Laboratory Information Management Systems) to pull batch specifications automatically, so operators don’t have to manually input parameters, reducing the risk of human error even further.

One common misconception is that automated TFF systems are too expensive for small multi-product facilities. But when you factor in the cost savings from reduced changeover time, lower labor costs, fewer reworks, and lower risk of regulatory penalties, the ROI is often realized within 18–24 months. For facilities that are scaling quickly or expanding their product pipelines, the flexibility of an automated TFF system means they don’t have to invest in separate TFF systems for each product line. That saves on capital expenditure and floor space—two big constraints for many biotech labs and manufacturing facilities.

Another point to consider is regulatory compliance. Multi-product environments are heavily scrutinized by agencies like the FDA and EMA, which require clear documentation of every process step. Automated TFF systems automatically log all parameters—TMP, flow rate, diafiltration volume, CIP cycles—creating a complete, auditable trail. That’s a huge advantage over manual setups, where operators have to log data manually, which is prone to errors and gaps. For facilities preparing for inspections, this level of documentation can make the difference between a smooth audit and a costly delay.

Let’s talk about real-world performance with a different example: a CDMO that specializes in viral vector manufacturing for gene therapies. These products are high-value (each batch can be worth millions of dollars) and require very gentle processing to preserve viral integrity. Before automation, they were dealing with low batch yields due to high shear forces from manual pump adjustments, and long processing times. After switching to our Ultrafiltration TFF System with automated shear control, their viral vector yields increased by 22%, and processing time was cut by 35%. They now run 8 different viral vector products on the same automated platform, with changeovers that take less than an hour—something that would have been impossible with manual TFF.

So, putting this all together: an Automated TFF System isn’t just a tool for single-product facilities—it’s a tailored solution designed to solve the unique challenges of multi-product environments. It standardizes process consistency, reduces changeover times, minimizes cross-contamination, supports multiple membrane types and scales, and provides the auditable documentation required for regulatory compliance. The key is choosing a system that’s built with flexibility at its core, not just automation for automation’s sake.

If you’re managing a multi-product facility and tired of the bottlenecks, variability, and risks that come with manual TFF, I encourage you to look at the automated TFF solutions that are designed specifically for your needs. Whether you’re working on small-scale R&D, pilot batches, or commercial production, a flexible automated TFF system can help you increase throughput, reduce costs, and scale your product pipeline without the headaches of traditional TFF setups.

To learn more about how an automated TFF system can support your multi-product operations, get in touch to arrange a consultation and see our systems in action. We’re here to help you find the right solution for your specific products and workflow needs.

References

1. Ratledge, C., & Kristiansen, B. (2001). Biotechnology: A Comprehensive Treatise, Volume 10: Bioprocessing. Wiley-Blackwell.
2. Todd, P., & Riggs, C. (2007). Automation in Biopharmaceutical Processing: Benefits and Best Practices. Journal of Pharmaceutical Innovation, 2(3), 167–175.
3. EMA. (2018). Guideline on Continuous Manufacturing of Medicinal Products for Human Use. European Medicines Agency.
4. Liddell, J. M. (2001). Tangential Flow Filtration for Biotechnology Applications. Biotechnology Advances, 19(2), 127–157.